课题基金 / 基金详情

Mechanisms of response and resistance to epigenetic therapy in hematological malignancy

Mechanisms of response and resistance to epigenetic therapy in hematological malignancy
血液恶性肿瘤表观遗传治疗的反应和耐药机制
批准号：
267371
负责人：
Miller Wilson H
金额：
$53.17万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2012
资助国家：
加拿大
项目状态：
已结题
起止时间：
2012-09-01 至 2017-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=267371&lang=en
关键词：
Autophagy Diffuse Large B Cell Lymphoma Epigenetic Drugs Er Stress Ezh2 Gene Repression Hematological Malignancy Histone Deacetylase Inhibtors Unfolded Protein Response

项目摘要

项目成果

Miller Wilson H的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In addition to the many differences in the genetic code that may determine health and disease, cells may modify the action of our genes by what are called epigenetic mechanisms. Epigenetic markers on our genetic material are important in normal heredity
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploring the therapeutic potential of combined inhibition of MNK1/2 and CDK4/6 to treat melanoma.
Targeting the Mnk/eIF4E axis in the tumor microenvironment of pregnancy associated breast cancers.
Understanding the role of the MNK-eIF4E axis in the response and resistance to BRAF inhibitors.
Targeting the eukaryotic translation initiation factor eIF4E with ribavirin in breast cancer
海外基金